Children and antimicrobial resistance(5)

22 November, 2020

It’s sad how Pharmaceutical companies are taking advantage of the weak regulatory system in the Sub Saharan African region to perpetuate this ethical misconduct. In my experience,

It’s not just antibiotics and probiotics; it goes into cardiovascular and drugs for many chronic diseases.

I had to challenge one of those drug reps in my clinic for advertising probiotics to show me how cost effective probiotics are compared with ORS. He couldn’t of course.

We need collaborative efforts to halt this before it becomes a bigger problem.

Chris Yilgwan

CHIFA Profile: C S Yilgwan is a Consultant Paediatrician Cardiologist at the Jos University Teaching Hospital in Nigeria.

Email: yilgwan AT